A Phase 2, Multicenter Study With Open-Label and Randomized Double-Blind Placebo-Controlled Withdrawal Phases to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms Who Are Clinically Stable and Taking Stable Doses of Atypical Antipsychotic Medication.

Trial Profile

A Phase 2, Multicenter Study With Open-Label and Randomized Double-Blind Placebo-Controlled Withdrawal Phases to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms Who Are Clinically Stable and Taking Stable Doses of Atypical Antipsychotic Medication.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
    • 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
    • 02 May 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top